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CONCLUSION: There is a substantial increase in the
management costs of AIDS in the last year of life.
PID3
ECONOMIC EVALUATION OF SYSTEMIC 
TREATMENTS FOR CMV RETINITIS IN PERSONS 
WITH AIDS IN SWITZERLAND
Lee TA1, Sullivan SD1, Ramsey SD1, Steger P2, Williamson T2, 
Pliel A2
1University of Washington, Seattle, WA, USA; 2Pharmacia and 
Upjohn, Kalamazoo, MI, USA
OBJECTIVE: To determine the cost impact of four sys-
temic regimens for the treatment of newly diagnosed cy-
tomegalovirus (CMV) retinitis in persons with AIDS. 
METHODS: An incidence-based simulation model was
developed to evaluate the economic implications of treat-
ing CMV retinitis from a government payer perspective.
The model randomly assigned patients to one of four sys-
temic treatment regimens for induction and maintenance
therapies: 1) ganciclovir IV/IV; 2) ganciclovir IV/PO; 3)
foscarnet IV/IV; and 4) cidofovir IV/IV. Following a sec-
ond relapse patients were randomly assigned an alterna-
tive therapy in order to assess the impact of various fail-
ure treatment strategies. Efficacy and safety data were
extracted from a systematic review of available literature
and publicly available sources. Resource use and cost
data were obtained from a large, AIDS treatment facility
in Switzerland. The primary outcome measures were time
to first and subsequent progression, duration of mainte-
nance treatment, and associated direct medical expendi-
tures (1998 Swiss francs). Nonmedical costs and quality
of life benefits were not considered. 
RESULTS: The median time to first progression was
greatest for cidofovir followed by foscarnet, ganciclovir
IV, and ganciclovir PO. The average 1-year costs in the
base case were lowest in patients initially randomized to
cidofovir (87,867 CHF) followed by randomization to
ganciclovir IV/PO (110,410 CHF), ganciclovir IV/IV
(117,406 CHF), and foscarnet IV/IV (120,662 CHF).
Sensitivity analyses of costs, effectiveness, and adverse
event rates resulted in changes in the cost estimates, how-
ever the order remained unchanged. 
CONCLUSIONS: Of the four treatment regimens stud-
ied, beginning treatment with systemic cidofovir is most
effective and least costly over a 1-year period.
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A RETROSPECTIVE DATABASE STUDY OF AIDS 
INITIAL TREATMENT REGIMENS, SWITCHING 
PATTERNS, AND PATIENT ADHERENCE
Hutchison S, Beno C
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Scottsdale, AZ, USA
OBJECTIVES: AIDS treatment specialists advocate ag-
gressive (triple drug therapy) treatment of HIV/AIDS, but
limited research suggests that this position is not widely
held. Database studies are being used increasingly to pro-
vide information about patient behavior (e.g., identifica-
tion of treatment regimens and adherence with treatment
regimens). 
METHODS: A retrospective database study was con-
ducted to identify initial treatment regimens prescribed
for patients, changes in treatment regimens over time,
and patient adherence to their treatment regimens. 
RESULTS: Two patient cohorts were identified: one initi-
ating therapy after triple drug therapy was introduced and
before it was advocated as the treatment of choice; and
one initiating therapy after triple drug therapy was advo-
cated by HHS and the AMA. AIDS drugs prescriptions
filled for a 12-month period following initiation of therapy
were extracted from the database for each patient cohort. 
RESULTS: Findings indicate that 1) triple drug therapy is
not widely prescribed as an initiation therapy, 2) after
initiating therapy many patients must switch or augment
their treatment regimens, and 3) after 12 months of ther-
apy the triple drug regimen is still not widely prescribed. 
CONCLUSIONS: The results of this study provide further
evidence of the utility of retrospective database studies to
provide healthcare providers with cost-effective healthcare
delivery information.
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DEVELOPMENT AND INITIAL ASSESSMENT OF 
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QUESTIONNAIRE-7 FOR USE IN 
INTERNATIONAL HIV STUDIES
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Data support the link between adherence to HIV treatment
and detectability of HIV RNA (a predictor of disease pro-
gression), making adherence a vital issue in HIV therapy. 
OBJECTIVE: To develop and assess a questionnaire to
measure adherence to HIV treatment. 
METHODS: Items from two existing measures, the Pa-
tient Medication Adherence Questionnaire (PMAQ) and
the Treatment Review and Satisfaction Questionnaire
(TRaSQ), were tested and revised using feedback from fo-
cus groups and in-depth interviews with 28 US and 29 Ital-
ian HIV-infected patients. This assessment highlighted is-
sues surrounding adherence, including patient beliefs,
knowledge and attitudes, lifestyle changes, medication
characteristics, regimen complexity, side effects, patient-
provider relationships, and patient recall. The subsequent
instrument, the PMAQ7, contains Likert-type items ad-
dressing these issues, and a behavioral assessment of ad-
herence over the past 7 days. 
RESULTS: Patients indicated that the PMAQ7 addressed
issues that were important to HIV patients, including side
effects and convenience of regimens. They added that an
issue’s importance could vary with the length of time that
a patient has been on HIV treatment. In addition, cultural
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differences became apparent regarding issues such as pri-
vacy, which was of greater concern to Italian patients than
US patients, and bureaucratic issues surrounding drug
availability, which were difficult for some US patients but
not for Italian patients. Finally, in response to patient sug-
gestions, the questionnaire includes positive wording
about “taking” rather than “missing” medication. 
CONCLUSION: In this small group of patients, the
PMAQ7 was judged to be relevant for patients, offering a
promising initial indication of the validity of the instru-
ment to monitor and manage adherence to antiretroviral
therapy.
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HEALTH-RELATED QUALITY OF LIFE CHANGES 
IN PATIENTS WITH ONYCHOMYCOSIS
Lubeck DP1, Doyle JJ2, Schein JR2, Potter LP3, Prebil LA3
1University of California/San Francisco, San Francisco, CA, 
USA; 2Novartis Pharmaceuticals Corporation, East Hanover, 
NJ, USA; 3Lewin-TAG, San Francisco, CA, USA
OBJECTIVES: The objective of the study was to examine
changes in health-related quality of life (HRQoL) in an
observational database of patients with onychomycosis
receiving various treatments by either dermatologists or
podiatrists. 
METHODS: Dermatologists or podiatrists at eight US
sites reported on clinical outcomes at baseline and follow-
up (4 and 9 months). Patients completed a validated
HRQoL questionnaire at the same time points that mea-
sured the impact of onychomycosis on generic (general
health perception, pain, mental health, social functioning,
health distress, physical functioning, and health transition)
and disease-specific items (toe symptom frequency, toe
symptom bother, problems with appearance, problems
with activities, stigma, and satisfaction with treatment). 
RESULTS: For this study 113 patients completed the
questionnaire at baseline and follow-up. Forty-eight per-
cent of patients were treated by dermatologists, 52% by
podiatrists. Patients were predominately male (58%). At
month 9, patients treated with oral antifungal therapy had
significant improvements in physical functioning, toenail
symptoms, toenail bother, problems with appearance and
activities, stigma, pain and satisfaction with treatment
(p  0.01) when compared with patients treated with non-
oral therapy. 
CONCLUSION: The data indicate that patients with on-
ychomycosis who seek treatment with oral therapy re-
port significant improvement in HRQoL and satisfaction
compared with patients treated with non-oral therapy.
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COST-EFFECTIVE ANALYSIS OF ORAL 
ONYCHOMYCOSIS THERAPIES USING IDAHO 
MEDICAID CLAIMS DATA
Alemao EA, Cady PS, Phatak HM, Culbertson VL
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OBJECTIVE: The purpose of this study was to evaluate
cost per mycological treatment of oral antifungal drugs
and to determine the most cost-effective primary treatment
for onychomycosis using the Idaho Medicaid claims data. 
METHOD: Oral griseofulvin, itraconazole, ketoconazole,
fluconazole, and terbinafine were the antifungal drugs used
to determine the cost per mycological treatment and relative
cost-effectiveness ratios. The Idaho Medicaid database was
screened using ICD-9 code, from October 1992 to Novem-
ber 1998 to identify patients receiving treatment for ony-
chomycosis. Five hundred and forty-nine patients using one
antifungal drug were identified and were followed for a pe-
riod of 1 year following a diagnosis of fungal infection of
the nail and an associated prescription of an antifungal
agent. Costs for drugs, physician visits, and drug manage-
ment was used in the treatment model. CPT codes were
used to identify laboratory cost involved in drug manage-
ment. The Mycological cure rates obtained from clinical tri-
als reported in literature were used as a measure of treat-
ment efficacy. Relative cost-effectiveness was calculated
assigning a value of 1.0 to terbinafine. 
RESULTS: The mean total treatment cost for each pa-
tient for griseofulvin was $460.72, for itraconazole was
$872.91, for ketoconazole was $464.78, for fluconazole
was $216.80, and that of terbinafine was $186.57. Ter-
binafine also had the lowest cost ($230.33) per mycolog-
ical treatment after adjusting for cure rates, for one treat-
ment regimen. Relative cost-effectiveness for griseofulvin
was 2.94, for itraconazole 4.07, for ketoconazole 3.36,
and fluconazole was 1.58. 
CONCLUSIONS: Terbinafine was found to be a more
cost-effective primary drug compared to griseofulvin,
itraconazole and ketoconazole in the treatment of ony-
chomycosis. Fluconazole was found to be the second
most cost-effective next to terbinafine.
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TREATMENT OF ONYCHOMYCOSIS OF THE 
NAIL IN A MEDICAID POPULATION
Phatak HM, Cady PS, Alemao EA, Culbertson VL
College of Pharmacy, Idaho State University, Pocatello, ID, USA
OBJECTIVE: A retrospective analysis to compare cost,
days of therapy, and demographic data for patients on
antifungal therapies for nail involvement in a Medicaid
population. 
METHOD: Diagnosis codes combined with antifungal
medications were used to identify patients on different
therapies for onychomycosis. Griseofulvin, itraconazole,
ketoconazole, fluconazole, and terbinafine were the oral
antifungal drugs compared. Drug costs and physician costs
were analyzed. The total number of different medications,
other than those for onychomycosis, was used as a mea-
sure of health. Demographic variables of age and gender
were evaluated. 
